Fortrea Holdings
FTRE
18.55
-1.60
-7.94%
Fortrea Holdings
US · FTRE
#2796 by market cap
Listed 2023
18.55
-1.60
-7.94%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Baird Maintains Fortrea Holdings(FTRE.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/10/30
-
Rating change
UBS Initiates Fortrea Holdings(FTRE.US) With Hold Rating, Announces Target Price $22Market Newswire · 2026/9/30
-
TD Cowen Maintains Fortrea Holdings(FTRE.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/11/3
-
Rating change
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Fortrea Holdings Inc. (FTRE)TipRanks · 2026/9/3
-
Rating change
Deutsche Bank Upgrades Fortrea Holdings(FTRE.US) to Buy Rating, Raises Target Price to $25Market Newswire · 2026/10/15
-
Rating change
Barclays Maintains Fortrea Holdings(FTRE.US) With Hold Rating, Maintains Target Price $22Market Newswire · 2026/9/3
-
Rating change
William Blair Maintains Fortrea Holdings(FTRE.US) With Hold RatingMarket Newswire · 2026/9/10
-
A Quick Look at Today's Ratings for Fortrea Holdings(FTRE.US), With a Forecast Between $26 to $28Market Newswire · 2026/10/31
-
Rating change
BofA Securities Maintains Fortrea Holdings(FTRE.US) With Sell Rating, Announces Target Price $15.5Market Newswire · 2026/10/9
-
Rating change
Barclays Maintains Fortrea Holdings(FTRE.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/10/30
-
Rating change
UBS Maintains Fortrea Holdings(FTRE.US) With Hold Rating, Maintains Target Price $22Market Newswire · 2026/10/3
-
Rating change
UBS Maintains Fortrea Holdings(FTRE.US) With Hold Rating, Raises Target Price to $24Market Newswire · 2026/10/20
-
Rating change
Truist Financial Maintains Fortrea Holdings(FTRE.US) With Buy RatingMarket Newswire · 2026/9/3
-
Rating change
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and Immunome (IMNM)TipRanks · 2026/9/10
-
Rating change
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)TipRanks · 2026/8/17
-
Barclays Maintains Fortrea Holdings(FTRE.US) With Buy Rating, Maintains Target Price $26Market Newswire · 2026/10/30
-
Mizuho Securities Downgrades Fortrea Holdings(FTRE.US) to Sell Rating, Raises Target Price to $19Market Newswire · 2026/11/11
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fortrea Holdings Inc. (FTRE), Medtronic (MDT) and Immunic (IMUX)TipRanks · 2026/9/2
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (PHR), Alpha Tau (DRTS) and Fortrea Holdings Inc. (FTRE)TipRanks · 2026/9/3
-
Rating change
Barclays Upgrades Fortrea Holdings(FTRE.US) to Buy Rating, Raises Target Price to $23Market Newswire · 2026/10/6
-
Rating change
TD Cowen Maintains Fortrea Holdings(FTRE.US) With Buy Rating, Maintains Target Price $23Market Newswire · 2026/8/4
-
GUIDANCE: (FTRE) Fortrea Expects 2026 Revenue Range $2.67B to $2.69B, Vs. FactSet Est of $2.66BMT Newswires · 2026/10/29
-
Rating change
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Fortrea Holdings Inc. (FTRE) and UniQure (QURE)TipRanks · 2026/7/30
-
Rating change
A Quick Look at Today's Ratings for Fortrea Holdings(FTRE.US), With a Forecast Between $22 to $26Market Newswire · 2026/7/31
-
Rating change
TD Cowen Maintains Fortrea Holdings(FTRE.US) With Buy Rating, Raises Target Price to $23Market Newswire · 2026/8/4
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.
Fortrea Holdings discussion 0 comments